Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Financial News

Merck KGaA spinout Calypso raises first tranche of €20M series A

February 21, 2019 12:20 AM UTC

Calypso Biotech B.V. (Amsterdam, the Netherlands) closed the first tranche of a €20 million ($22.6 million) series A round Wednesday, with enough funding to begin clinical studies of its lead candidate to treat eosinophilic esophagitis.

The round was led by Gilde Healthcare Partners and INKEF Capital, who joined Johnson & Johnson Innovation - JJDC Inc. and founding investor M Ventures, the investment arm of Merck KGaA (Xetra:MRK)...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Calypso Biotech B.V.

Merck KGaA

BCIQ Target Profiles

Interleukin-15 (IL-15)